Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy

• Main Authors: Hui-Zi Chen, MD, PhD, Russell Bonneville, BS, Anoosha Paruchuri, PhD, Julie W. Reeser, PhD, Michele R. Wing, PhD, Eric Samorodnitsky, PhD, Melanie A. Krook, PhD, Amy M. Smith, BS, Thuy Dao, BS, Jharna Miya, MS, Walter Wang, BS, Lianbo Yu, PhD, Aharon G. Freud, MD, PhD, Patricia Allenby, MD, Sharon Cole, MD, Gregory Otterson, MD, Peter Shields, MD, David P. Carbone, MD, PhD, Sameek Roychowdhury, MD, PhD
• Format: Article
• Language: English
• Published: Elsevier 2021-04-01
• Series: JTO Clinical and Research Reports
• Subjects: Small cell lung cancer; Research autopsy; Tumor heterogeneity; Treatment resistance
• Online Access: http://www.sciencedirect.com/science/article/pii/S2666364321000230

Introduction: Relapsed SCLC is characterized by therapeutic resistance and high mortality rate. Despite decades of research, mechanisms responsible for therapeutic resistance have remained elusive owing to limited tissues available for molecular studies. Thus, an unmet need remains for molecular characterization of relapsed SCLC to facilitate development of effective therapies. Methods: We performed whole-exome and transcriptome sequencing of metastatic tumor samples procured from research autopsies of five patients with relapsed SCLC. We implemented bioinformatics tools to infer subclonal phylogeny and identify recurrent genomic alterations. We implemented immune cell signature and single-sample gene set enrichment analyses on tumor and normal transcriptome data from autopsy and additional primary and relapsed SCLC data sets. Furthermore, we evaluated T cell-inflamed gene expression profiles in neuroendocrine (ASCL1, NEUROD1) and non-neuroendocrine (YAP1, POU2F3) SCLC subtypes. Results: Exome sequencing revealed clonal heterogeneity (intertumor and intratumor) arising from branched evolution and identified resistance-associated truncal and subclonal alterations in relapsed SCLC. Transcriptome analyses further revealed a noninflamed phenotype in neuroendocrine SCLC subtypes (ASCL1, NEUROD1) associated with decreased expression of genes involved in adaptive antitumor immunity whereas non-neuroendocrine subtypes (YAP1, POU2F3) revealed a more inflamed phenotype. Conclusions: Our results reveal substantial tumor heterogeneity and complex clonal evolution in relapsed SCLC. Furthermore, we report that neuroendocrine SCLC subtypes are immunologically cold, thus explaining decreased responsiveness to immune checkpoint blockade. These results suggest that the mechanisms of innate and acquired therapeutic resistances are subtype-specific in SCLC and highlight the need for continued investigation to bolster therapy selection and development for this cancer.